Bio-Techne to Present at Upcoming Investor Conferences
Bio-Techne (NASDAQ: TECH) has announced its participation in three major healthcare investor conferences in September 2025.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Bio-Techne (NASDAQ: TECH) has announced its participation in three major healthcare investor conferences in September 2025. The company will present at the Wells Fargo Healthcare Conference on September 3 at 10:15 AM EDT, the Baird Global Healthcare Conference on September 9 at 9:05 AM EDT, and the Morgan Stanley Global Healthcare Conference on September 10 at 10:45 AM EDT.
Investors can access live webcasts of all presentations through Bio-Techne's Investor Relations website under the IR Calendar page.
Details
News Market Reaction – TECH
On Aug 27, the day this news came out, TECH closed 1.00% below the previous close.
Data tracked by StockTitan Argus for the Aug 27 session.
AI-generated analysis. How Rhea-AI works. Not financial advice.
2025 Wells Fargo Healthcare Conference
September 3, 2025
10:15 AM EDT
Baird 2025 Global Healthcare Conference
September 9, 2025
9:05 AM EDT
Morgan Stanley 23rd Annual Global Healthcare Conference
September 10, 2025
10:45 AM EDT
A live webcast of the presentations can be accessed via the IR Calendar page of Bio-Techne's Investor Relations website at https://investors.bio-techne.com/ir-calendar.
About Bio-Techne
Bio-Techne Corporation (NASDAQ: TECH) is a global life sciences company providing innovative tools and bioactive reagents for the research and clinical diagnostic communities. Bio-Techne products assist scientific investigations into biological processes and the nature and progress of specific diseases. They aid in drug discovery efforts and provide the means for accurate clinical tests and diagnoses. With hundreds of thousands of products in its portfolio, Bio-Techne generated over
Contact: David Clair, Vice President, Investor Relations & Corporate Development
david.clair@bio-techne.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/bio-techne-to-present-at-upcoming-investor-conferences-302539292.html
SOURCE Bio-Techne Corporation
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.